Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PFE

Covered Call Screener Results For Dec 10th

Covered calls are a great strategy to add to any portfolio, and can offer enhanced yield from stock holdings, in some case, that can be a significant increase.

How the EPP ushered in a right-wing majority at the European Parliament

How the EPP ushered in a right-wing majority at the European Parliament

For the first time, a right-wing majority is emerging at the European Parliament as the European People's Party flirts with groups that would have been considered too toxic to work with in the past. The pivot has given the EPP a choice but also created a headache for Ursula von…

EPP teams up with far right to water down reporting requirements for companies

EPP teams up with far right to water down reporting requirements for companies

The European Parliament approved a package to ease corporate sustainability reporting and due diligence requirements. EPP teamed up with conservative and far-right MEPs to pass the law.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter 2025 adjusted earnings of 87 cents, compared to $1.06 a year ago, beating the consensus of 63 cents.

Pfizer Stock: Is Wall Street Bullish or Bearish?

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Pfizer Seeks Expanded Use Approval For Breast Cancer Drug

Pfizer Inc. (NYSE:PFE) on Tuesday announced the initial results from a clinical trial called HER2CLIMB-05.

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

inkl

Read news from The Economist, FT, and more,
with one subscription

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.

Votes of confidence: Which political groups will defend von der Leyen?

Votes of confidence: Which political groups will defend von der Leyen?

The European Commission is set to survive the two motions of censure to be voted on Thursday. But its support could shrink even more.

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

Top 3 Dividend Achievers for October: High Yields, Growth Ahead

Top 3 Dividend Achievers for October: High Yields, Growth Ahead

High-yield Dividend Achievers, such as United Parcel Service, Verizon, and Pfizer, offer attractive entry points in October for income investors.

Pfizer Shares Are Trading Higher Wednesday: What's Going On?

Pfizer (NYSE:PFE) shares are trading higher Wednesday after President Donald Trump announced a drug-pricing deal with the company.

Stock Of The Day: Will Pfizer Head Higher?

Shares of Pfizer Inc. (NYSE:PFE) continue to head higher on Wednesday, a day after the company announced that it has secured a three-year grace period from President Donald Trump's tariffs on pharmaceuticals. This will enable Pfizer to offer its medication at significantly discounted prices compared to current rates.

Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away

Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a…

Get all your
news in one place.

100’s of premium titles.
One news app.

Lithium Americas, Nike, Pfizer, CoreWeave And Occidental Petroleum: Why These 5 Stocks Are On Investors' Radars Today

The U.S. stock market brushed aside worries over a potential government shutdown and advanced on Tuesday. The Dow Jones Industrial Average gained nearly 0.2% to 46,397.89, the SP 500 climbed about 0.4% to 6,688.46, and the Nasdaq rose 0.3% to 22,660.These are the top stocks that gained the attention of…

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

Pfizer Faces Court Over Depo-Provera Brain Tumor Claims

Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key court hearing set for late September that could determine whether affected women can pursue their cases in court.

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

Get all your
news in one place.

100’s of premium titles.
One news app.

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases.

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Patriots for Europe submit no-confidence motion against the European Commission

The Eurosceptic group has collected enough signatures to kick off a motion of censure. Von der Leyen will face Parliament’s verdict in October.

Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults.

Fresh no-confidence votes stalk EU's Ursula von der Leyen

The radical Left and far-right are about to present two different motions of censure against the Commission. A first vote is expected in October.

European Parliament seeks recovery from Patriots of EU funds misused by previous far-right group

The group that includes France’s Rassemblement National, Italy’s The League, and Hungary’s Fidesz could be obliged to repay over €4 million.

Is Pfizer Stock Underperforming the Nasdaq?

Although Pfizer has underperformed the Nasdaq recently, analysts remain moderately optimistic about the stock’s prospects.

People

155,629 stories

Ursula von der Leyen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

the European Commission

European Parliament

the European Parliament

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Government Shutdown

Dow Jones Industrial Average

Places

324,748 stories

Washington D.C.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play